Characterization of antibodies to SARS-CoV-2 in lyophilized plasma prepared with amotosalen-UVA pathogen reduction.
plasma derivatives
transfusion-transmitted disease
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
26
06
2023
received:
07
04
2023
accepted:
26
06
2023
medline:
14
9
2023
pubmed:
24
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected patients exhibit disease ranging from asymptomatic to severe pneumonia, multi-organ failure, and death. convalescent COVID plasma (CCP) from recovered patients with high levels of neutralizing antibodies has demonstrated therapeutic efficacy to reduce the morbidity of coronavirus disease 2019 (COVID-19) in some studies. The development of assays to characterize the activity of CCP to neutralize SARS-CoV-2 infectivity offers the possibility to improve potential therapeutic efficacy. Lyophilization of CCP may increase the availability of this therapy. We hypothesized that SARS-CoV-2 antibody profiles of pooled lyophilized pathogen-reduced CCP from COVID-19-recovered blood donors retains virus-neutralizing efficacy as reported for frozen pathogen-reduced CCP. Pooled lyophilized pathogen-reduced plasma was prepared from recovered COVID plasma donors. Antibodies to SARS-CoV-2 were characterized in each donor plasma prior to pathogen reduction and lyophilization and after lyophilization of individual CCP, and in the lyophilized CCP pool. Several complimentary assays were used to characterize antibody levels, neutralizing capacity, and the spectrum of antigen reactivity. The mean values for individual plasma samples and the value in the pool were compared. The mean ratio for antibody binding to SARS-CoV-2 antigens before and after treatment was 0.95 ± 0.22 mean fluorescent intensity (MFI) units. Antibody activity to an array of influenza virus antigens demonstrated a mean activity ratio of 0.92 ± 0.12 MFI before and after treatment. The antibody activity in pooled pathogen-reduced lyophilized CCPs demonstrated minimal impact due to pathogen reduction treatment and lyophilization.
Sections du résumé
BACKGROUND
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected patients exhibit disease ranging from asymptomatic to severe pneumonia, multi-organ failure, and death. convalescent COVID plasma (CCP) from recovered patients with high levels of neutralizing antibodies has demonstrated therapeutic efficacy to reduce the morbidity of coronavirus disease 2019 (COVID-19) in some studies. The development of assays to characterize the activity of CCP to neutralize SARS-CoV-2 infectivity offers the possibility to improve potential therapeutic efficacy. Lyophilization of CCP may increase the availability of this therapy. We hypothesized that SARS-CoV-2 antibody profiles of pooled lyophilized pathogen-reduced CCP from COVID-19-recovered blood donors retains virus-neutralizing efficacy as reported for frozen pathogen-reduced CCP.
METHODS
Pooled lyophilized pathogen-reduced plasma was prepared from recovered COVID plasma donors. Antibodies to SARS-CoV-2 were characterized in each donor plasma prior to pathogen reduction and lyophilization and after lyophilization of individual CCP, and in the lyophilized CCP pool. Several complimentary assays were used to characterize antibody levels, neutralizing capacity, and the spectrum of antigen reactivity. The mean values for individual plasma samples and the value in the pool were compared.
RESULTS
The mean ratio for antibody binding to SARS-CoV-2 antigens before and after treatment was 0.95 ± 0.22 mean fluorescent intensity (MFI) units. Antibody activity to an array of influenza virus antigens demonstrated a mean activity ratio of 0.92 ± 0.12 MFI before and after treatment.
CONCLUSIONS
The antibody activity in pooled pathogen-reduced lyophilized CCPs demonstrated minimal impact due to pathogen reduction treatment and lyophilization.
Substances chimiques
amotosalen
K1LDZ0VBC0
Furocoumarins
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1633-1638Informations de copyright
© 2023 AABB.
Références
Chu J, Yang N, Wei Y, Yue H, Zhang F, Zhao J, et al. Clinical characteristics of 54 medical staff with COVID-19: a retrospective study in a single center in Wuhan, China. J Med Virol. 2020;92:807-813.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323:1582.
Hueso T, Pouderoux C, Pere H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136:2290-2295.
Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384:1015-1027.
Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med. 2022;386:1700-1711.
Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020;105:2834-2840.
Libster R, Perez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610-618.
Weisser M, Khanna N, Hedstueck A, Sutter ST, Roesch S, Stehle G, et al. Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients. Transfusion. 2022;62:1997-2011.
Peto L, Horby P, Landray M. Establishing COVID-19 trials at scale and pace: experience from the RECOVERY trial. Adv Biol Regul. 2022;86:100901.
Bagri A, de Assis RR, Tsai CT, et al. Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment. Transfusion. 2022;62:570-583.
Estcourt LJ, Cohn CS, Pagano MB, Iannizzi C, Kreuzberger N, Skoetz N, et al. Clinical practice guidelines from the Association for the Advancement of blood and biotherapies (AABB): COVID-19 convalescent plasma. Ann Intern Med. 2022;175:1310-1321.
Martinaud C, Ausset S, Deshayes AV, Cauet A, Demazeau N, Sailliol A. Use of freeze-dried plasma in French intensive care unit in Afghanistan. J Trauma. 2011;71:1761-1765.
Martinaud C, Civadier C, Ausset S, Verret C, Deshayes AV, Sailliol A. In vitro hemostatic properties of French lyophilized plasma. Anesthesiology. 2012;117:339-346.
Tonn T, Corman VM, Johnsen M, Richter A, Rodionov RN, Drosten C, et al. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma. Lancet Microbe. 2020;1:e63.
Larrea L, Castro E, Navarro L, Vera B, Francés-Gómez C, Sánchez-Sendra B, et al. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light. Blood Transfus. 2022;20:206-212.
Conan PL, Ficko C, Chueca M, Rolland C, Javaudin O, Bigaillon C, et al. COVID-19 repeated convalescent plasma collection: analysis of 149 donations from 88 French military health workers. Transfus Med Hemother. 2021;395:1-6.
Danh K, Karp DG, Singhal M, Tankasala A, Gebhart D, de Jesus Cortez F, et al. Detection of neutralizing antibodies against multiple SARS-CoV-2 strains in dried blood spots using cell-free PCR. Nat Commun. 2022;13:4212.
de Assis RR, Jain A, Nakajima R, Jasinskas A, Felgner J, Obiero JM, et al. Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. Nat Commun. 2021;12:6.
Flaumenhaft EJ, Khat T, Marschner S. Retention of coagulation factors and storage of freeze-dried plasma. Mil Med. 2021;186:400-407.
Sheffield WP, Bhakta V, Howell A, Jenkins C, Serrano K, Johnson N, et al. Retention of hemostatic and immunological properties of frozen plasma and COVID-19 convalescent apheresis fresh-frozen plasma produced and freeze-dried in Canada. Transfusion. 2022;62:418-428.
Farcet MR, Karbiener M, Knotzer S, Schwaiger J, Kreil TR. Omicron severe acute respiratory syndrome coronavirus 2 neutralization by immunoglobulin preparations manufactured from plasma collected in the United States and Europe. J Infect Dis. 2022;226:1396-1400.
Karbiener M, Farcet MR, Schwaiger J, Powers N, Lenart J, Stewart JM, et al. Highly potent SARS-CoV-2 neutralization by intravenous immunoglobulins manufactured from post-COVID-19 and COVID-19-vaccinated plasma donations. J Infect Dis. 2021;224:1707-1711.
U.S. Food and Drug Administration. In: Center for Biologics Evaluation and Research, editor. Considerations for the development of dried plasma products intended for transfusion: draft guidance for industry. Silver Spring, MD: U.S. FDA; 2018.